NCT05494359Completed
The Diagnostic Value of Nitrogen Element (N) in Esophagus Cancer
The Diagnostic Value of Various Mass Nitrogen Components Excreting for Oral Gas in Esophagus Cancer
Source: ClinicalTrials.gov · Last updated 14 Jul 2025
Brief summary (registry, in English)
The purpose of this study is to determine the diagnostic value of various nitrogen components in oral gas for esophagus cancer (ESCA) .
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 120 (actual)
- First submitted
- 7 Aug 2022
- Start date
- Apr 2023
- Primary completion date
- Nov 2024
- Lead sponsor
- Hepatopancreatobiliary Surgery Institute of Gansu Province
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT05494359
What you commit to
- Study type: Observational
- Participants enrolled: 120
- From Apr 2023 to the primary completion date, Nov 2024
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Esophageal or gastric surgery
- History of previous upper abdominal surgery
- History of previous gastrectomy, endoscopic mucosal resection or endoscopic submucosal dissection
- History of previous neoadjuvant chemotherapy or radiotherapy
- Long-term Chinese medicine treatment of unknown drug nature
Other illness
- History of other malignant disease within past five years
- History of unstable angina or myocardial infarction within past six months
- History of cerebrovascular accident within past six months
- Requirement of simultaneous surgery for other disease
- Emergency surgery due to complication (bleeding, obstruction or perforation) caused by cancer
- Severe mental disorder
Lab values
- Unstable vital signs Coagulation dysfunction (INR\>1.5)
- Low peripheral blood platelet or using anti coagulation drugs
Other
- Pregnant women or breastfeeding
- Unwillingness or inability to consent for the study
Who the study is looking for
- Esophageal cancer patients (Case): Subject diagnosed with ESCA based on typical clinical symptoms, endoscopic observation of esophageal lesions, and histopathological examination of biopsy specimens obtained from the lesion sites.
- Reflux esophagitis patients (Case control): Subject diagnosed diagnosed with reflux esophagitis based on typical clinical symptoms (e.g., heartburn and acid regurgitation) and endoscopic evidence of esophageal mucosal injury classified according to the Los Angeles classification system (Grade A: mucosal breaks ≤5 mm in length; Grade B: mucosal breaks \>5 mm in length but not confluent; Grade C: confluent mucosal breaks involving \<75% of the esophageal circumference; Grade D: confluent mucosal breaks involving ≥75% of the esophageal circumference).
- Health people: (Healthy control): no history of malignant tumors within the past five years, normal findings on gastroscopy, with no evidence of esophageal or gastric lesions, no history of gastrointestinal diseases such as gastroesophageal reflux disease (GERD) or Barrett's esophagus, blood counts, tumor biomarkers, and liver and kidney function tests within normal ranges.
Age in the registry: 18 years to 80 years · Sex: All · Accepts healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hepatopancreatobiliary Surgery Institute of Gansu Province Coordinator of this site? Confirm its status | Lanzhou | China | Unknown status |
| Clinical Research Centre, The Seventh Affiliated Hospital Coordinator of this site? Confirm its status | Shenzhen | China | Unknown status |
| Wuwei Tumor Hospital Coordinator of this site? Confirm its status | Wuwei | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.